A carregar...
Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) is a universal event and limits clinical efficacy. The third-generation EGFR inhibitor osimertinib is active in EGFR-mutant/T790M positive non-small-cell lung cancer. Mechanisms of acquired resistance are...
Na minha lista:
| Publicado no: | Lung Cancer (Auckl) |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5723122/ https://ncbi.nlm.nih.gov/pubmed/29255376 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S147129 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|